Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms

Carvalho, Cláudia; Vieira-Coelho, Maria Augusta

doi:10.1016/j.phrs.2022.106258

Cited by 19 publications

(12 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the confounding factor in this case was the use of cannabis, which is known to be an independent risk factor for psychotic illness 14 . Besides other risk factors, genetic vulnerability for cannabis‐related psychosis has been reported 15 . The role of substance misuse, especially cannabis, in patients with TOF who may be already genetically vulnerable to psychiatric illnesses may be explored.…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

Psychosis treatment in the context of tetralogy of Fallot and prolonged QTc

D’Souza

Kar

Jiwanmall

2023

Prog Neurol Psychiatry

View full text Add to dashboard Cite

We present a case of a 27‐year‐old Caucasian male with a background of surgically corrected tetralogy of Fallot (TOF) and pulmonary valve regurgitation, who presented with psychotic symptoms. The case presented a challenge in treatment due to the patient's cardiac history and ongoing cardiac‐related health problems with prolonged QTc before initiation of the antipsychotic drug. Treatment included careful monitoring of ECG while on antipsychotics, which led gradually to improvement in his mental state. The case highlights the possibility of a link between TOF and psychosis, the vulnerability of such patients to their treatment and the importance of multidisciplinary support for cardiac side‐effects.

show abstract

Section: Discussionmentioning

confidence: 86%

“…14 Besides other risk factors, genetic vulnerability for cannabis-related psychosis has been reported. 15 The role of substance misuse, especially cannabis, in patients with TOF who may be already genetically vulnerable to psychiatric illnesses may be explored.…”

Section: Tof and Psychosismentioning

confidence: 99%

Psychosis treatment in the context of tetralogy of Fallot and prolonged QTc

D’Souza

Kar

Jiwanmall

2023

Prog Neurol Psychiatry

View full text Add to dashboard Cite

show abstract

“…Many additional genes have been associated with cannabis use disorders and cannabis induced changes in executive functions. The following genes have demonstrated a positive association: DAT1 , SLC6A4 , DRD2 , DRD4 , BDNF , CHRM3 , P2RX7 , FAAH , ANKFN1 , SLC35G1 , CSMD1 , ANKK1 , COX2 , ABHD6 , ABHD12 , MAPK14 , SDK1 , ZNF704 , NCAM1 , RABEP2 , ATP2A1 , ATP2C2 , and SMG6 [ 46 , 402 , 406 , 417 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 ]. However, data on the effect of the polymorphisms of these genes are limited and controversial [ 419 , 429 , 436 , 437 ].…”

Section: Other Genes Of Interestmentioning

confidence: 99%

Cannabis Pharmacogenomics: A Path to Personalized Medicine

Babayeva

Loewy

2023

CIMB

View full text Add to dashboard Cite

Cannabis and related compounds have created significant research interest as a promising therapy in many disorders. However, the individual therapeutic effects of cannabinoids and the incidence of side effects are still difficult to determine. Pharmacogenomics may provide the answers to many questions and concerns regarding the cannabis/cannabinoid treatment and help us to understand the variability in individual responses and associated risks. Pharmacogenomics research has made meaningful progress in identifying genetic variations that play a critical role in interpatient variability in response to cannabis. This review classifies the current knowledge of pharmacogenomics associated with medical marijuana and related compounds and can assist in improving the outcomes of cannabinoid therapy and to minimize the adverse effects of cannabis use. Specific examples of pharmacogenomics informing pharmacotherapy as a path to personalized medicine are discussed.

show abstract

“…In a recent review, Carvalho et al (2022) highlighted that most candidate gene work has been mainly directed toward dopaminergic pathways. It is essential to expand the range of genetic research (Carvalho and Vieira-Coelho, 2022).…”

Section: Genetic Substrates Of Cannabis-associated Psychosismentioning

confidence: 99%

Genetic substrates of cannabis-associated psychosis

Quattrone

2022

RED

View full text Add to dashboard Cite

This paper will summarise the main substrates of cannabis-associated psychoses. First, an epistemological framework will be introduced to support the existence of a specific ‘cannabisassociated psychosis’ as a nosological entity distinct from idiopathic schizophrenia and other psychotic disorders. Then, the main clinical characteristics of cannabis-associated psychoses will be examined. Finally, the biological and genetic correlates of cannabis-associated psychosis will be presented.

show abstract

Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms

Cited by 19 publications

References 67 publications

Psychosis treatment in the context of tetralogy of Fallot and prolonged QTc

Psychosis treatment in the context of tetralogy of Fallot and prolonged QTc

Cannabis Pharmacogenomics: A Path to Personalized Medicine

Genetic substrates of cannabis-associated psychosis

Contact Info

Product

Resources

About